Global epidemiology of atrial fibrillation

Nature Reviews Cardiology

Volumn 11, Issue 11, 2014, Pages 639-654

  Rahman, Faisal ^a   Kwan, Gene F ^a   Benjamin, Emelia J ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN;

AFRICA; AGE; AGING; ANTICOAGULANT THERAPY; ARGENTINA; ASIA; AUSTRALIA; BLEEDING; BRAZIL; CAMEROON; CANADA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHINA; COGNITIVE DEFECT; DENMARK; DEVELOPING COUNTRY; DIABETES MELLITUS; EPIDEMIOLOGICAL DATA; ETHIOPIA; ETHNIC DIFFERENCE; ETHNICITY; GENDER; GEOGRAPHY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; INDIA; INDONESIA; ISCHEMIC HEART DISEASE; JAPAN; JORDAN; KENYA; LOWEST INCOME GROUP; MIDDLE EAST; MORTALITY; NEPAL; NIGERIA; OBESITY; PAKISTAN; PREVALENCE; PROGNOSIS; QATAR; REVIEW; RHEUMATIC HEART DISEASE; RISK FACTOR; SOUTH KOREA; SWEDEN; TANZANIA; THAILAND; THROMBOEMBOLISM; TURKEY (REPUBLIC); UNITED KINGDOM; UNITED STATES; VALVULAR HEART DISEASE; VENEZUELA; WESTERN HEMISPHERE; ATRIAL FIBRILLATION; COMPLICATION; COST OF ILLNESS; HEALTH; STATISTICS AND NUMERICAL DATA; STROKE;

ATRIAL FIBRILLATION; COST OF ILLNESS; GLOBAL HEALTH; HUMANS; PREVALENCE; RISK FACTORS; STROKE;

EID: 84908240457     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.118     Document Type: Review

References (258)

1. Einthoven, W. Le telecardiogramme [French]. Arch. Int. Physiol. 4, 132-164 (1906).
2. Lewis, T. Report CXIX. Auricular fibrillation: a common clinical condition. Br. Med. J. 2, 1528 (1909).
3. Piccini, J. P. et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ. Cardiovasc. Qual. Outcomes 5, 85-93 (2012).
4. Friberg, L. & Bergfeldt, L. Atrial fibrillation prevalence revisited. J. Intern. Med. 274, 461-468 (2013).
5. Krijthe, B. P. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 34, 2746-2751 (2013).
6. Sturm, J. W., Davis, S. M., OSullivan, J. G., Vedadhaghi, M. E. & Donnan, G. A. The Avoid Stroke as Soon as Possible (ASAP) general practice stroke audit. Med. J. Aust. 176, 312-316 (2002).
7. Deif, B., Lowres, N. & Freedman, S. B. Screening for atrial fibrillation above age 65 detects an asymptomatic subset at high risk of stroke. Int. J. Cardiol. 164, 371-372 (2013).
8. Friberg, L. et al. Population screening of 75-and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace 15, 135-140 (2013).
9. Fitzmaurice, D. A. et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 335, 383 (2007).
10. Lowres, N., Neubeck, L., Redfern, J. & Freedman, S. B. Screening to identify unknown atrial fibrillation. A systematic review. Thromb. Haemost. 110, 213-222 (2013).
11. Stewart, S., Hart, C. L., Hole, D. J. & McMurray, J. J. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med. 113, 359-364 (2002).
12. Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137, 263-272 (2010).
13. Soliman, E. Z. et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern. Med. 174, 107-114 (2014).
14. Miyasaka, Y. et al. Coronary ischemic events after first atrial fibrillation: risk and survival. Am. J. Med. 120, 357-363 (2007).
15. Miyasaka, Y. et al. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur. Heart J. 27, 936-941 (2006).
16. Kwok, C. S., Loke, Y. K., Hale, R., Potter, J. F. & Myint, P. K. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology 76, 914-922 (2011).
17. Udompanich, S., Lip, G. Y., Apostolakis, S. & Lane, D. A. Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. QJM 106, 795-802 (2013).
18. Bansal, N. et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127, 569-574 (2013).
19. Watanabe, H. et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata Preventive Medicine Study. Am. Heart J. 158, 629-636 (2009).
20. Benjamin, E. J. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98, 946-952 (1998).
21. Miyasaka, Y. et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J. Am. Coll. Cardiol. 49, 986-992 (2007).
22. Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285, 2370-2375 (2001).
23. The World Bank. Health, Nutrition and Population Data and Statistics [online], http://datatopics.worldbank.org/hnp/ (2012).
24. Moran, A. et al. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the Coronary Heart Disease Policy Model-China. Circ. Cardiovasc. Qual. Outcomes 3, 243-252 (2010).
25. Miyasaka, Y. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114, 119-125 (2006).
26. Kim, M. H., Johnston, S. S., Chu, B. C., Dalal, M. R. & Schulman, K. L. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ. Cardiovasc. Qual. Outcomes 4, 313-320 (2011).
27. Chugh, S. S. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129, 837-847 (2013).
28. Colilla, S. et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am. J. Cardiol. 112, 1142-1147 (2013).
29. Naccarelli, G. V., Varker, H., Lin, J. & Schulman, K. L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol. 104, 1534-1539 (2009).
30. DeWilde, S., Carey, I. M., Emmas, C., Richards, N. & Cook, D. G. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 92, 1064-1070 (2006).
31. Health & Social Care Information Centre. Quality and Outcomes Framework2009-2010, England level [online], http://www.hscic.gov.uk/catalogue/PUB05551 (2010).
32. Majeed, A. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart 86, 284-288 (2001).
33. Stefansdottir, H., Aspelund, T., Gudnason, V. & Arnar, D. O. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 13, 1110-1117 (2011).
34. Ohsawa, M. et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J. Epidemiol. 15, 194-196 (2005).
35. Inoue, H. et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int. J. Cardiol. 137, 102-107 (2009).
36. Zhou, Z. & Hu, D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J. Epidemiol. 18, 209-216 (2008).
37. United States Census Bureau. International Data Base [online], http://www.census.gov/population/international/data/idb/region.php?N.=%20Results%20&T=13&A=separate&RT=0&Y=2013&R.=-1&C=AS (2012).
38. Tse, H. F. et al. Stroke prevention in atrial fibrillation an Asian stroke perspective. Heart Rhythm 10, 1082-1088 (2013).
39. The World Bank. Low & middle income [online], http://data.worldbank.org/income-level/LMY (2014).
40. Institute for Health Metrics and Evaluation. GBD Compare [online], http://viz.healthmetricsandevaluation.org/gbd-compare/ (2013).
41. Moran, A. et al. The epidemiology of cardiovascular diseases in sub-Saharan Africa: the Global Burden of Diseases, Injuries and Risk Factors 2010 Study. Prog. Cardiovasc. Dis. 56, 234-239 (2013).
42. Sriharibabu, M., Himabindu, Y. & Kabir, Z. Rheumatic heart disease in rural south India: a clinico-observational study. J. Cardiovasc. Dis. Res. 4, 25-29 (2013).
43. Flaker, G. C. et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am. Heart J. 149, 657-663 (2005).
44. Alhadramy, O. et al. Prevalence and predictors of paroxysmal atrial fibrillation on Holter monitor in patients with stroke or transient ischemic attack. Stroke 41, 2596-2600 (2010).
45. Kishore, A. et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 45, 520-526 (2014).
46. Senoo, K. et al. Progression to the persistent form in asymptomatic paroxysmal atrial fibrillation. Circ. J. 78, 1121-1126 (2014).
47. Glotzer, T. V. et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 107, 1614-1619 (2003).
48. Ziegler, P. D. et al. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke 41, 256-260 (2010).
49. Wong, J. & Fong, A. Prevalence of asymptomatic atrial fibrillation in Malaysian patients with hypertension. Med. J. Malaysia 68, 141-143 (2013).
50. Marcus, G. M. et al. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation 122, 2009-2015 (2010).
51. Sinner, M. F., Ellinor, P. T., Meitinger, T., Benjamin, E. J. & Kaab, S. Genome-wide association studies of atrial fibrillation: past, present, and future. Cardiovasc. Res. 89, 701-709 (2011).
52. Shen, A. Y. et al. Racial/ethnic differences in the prevalence of atrial fibrillation among older adultsa cross-sectional study. J. Natl Med. Assoc. 102, 906-913 (2010).
53. Hernandez, M. B., Asher, C. R., Hernandez, A. V. & Novaro, G. M. African American race and prevalence of atrial fibrillation: a meta-analysis. Cardiol. Res. Pract. 2012, 275624 (2012).
54. Alonso, A. et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am. Heart J. 158, 111-117 (2009).
55. Dewland, T. A., Olgin, J. E., Vittinghoff, E. & Marcus, G. M. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation 128, 2470-2477 (2013).
56. Jensen, P. N., Thacker, E. L., Dublin, S., Psaty, B. M. & Heckbert, S. R. Racial differences in the incidence of and risk factors for atrial fibrillation in older adults: the cardiovascular health study. J. Am. Geriatr. Soc. 61, 276-280 (2013).
57. Lip, G. et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br. J. Gen. Pract. 47, 285-289 (1997).
58. Lip, G. Y. et al. Atrial fibrillation amongst the IndoAsian general practice population. The West Birmingham Atrial Fibrillation Project. Int. J. Cardiol. 65, 187-192 (1998).
59. Lau, C. P. et al. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J. Cardiovasc. Electrophysiol. 24, 381-387 (2013).
60. Jeong, J. H. Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years J. Korean Med. Sci. 20, 26-30 (2005).
61. Kiatchoosakun, S., Pachirat, O., Chirawatkul, A., Choprapawan, C. & Tatsanavivat, P. Prevalence of cardiac arrhythmias in Thai community. J. Med. Assoc. Thai. 82, 727-733 (1999).
62. Assantachai, P., Panchavinnin, P. & Pisalsarakij, D. An electrocardiographic survey of elderly Thai people in the rural community. J. Med. Assoc. Thai. 85, 1273-1279 (2002).
63. Kawabata-Yoshihara, L. A. et al. Prevalence of electrocardiographic findings in elderly individuals: the So Paulo Aging & Health Study. Arq. Bras. Cardiol. 93, 602-607 (2009).
64. Dewhurst, M. J. et al. Strikingly low prevalence of atrial fibrillation in elderly Tanzanians. J. Am. Geriatr. Soc. 60, 1135-1140 (2012).
65. Shavadia, J. et al. Clinical characteristics and outcomes of atrial fibrillation and flutter at the Aga Khan University Hospital, Nairobi: cardiovascular topics. Cardiovasc. J. Afr. 24, 6-9 (2013).
66. Kaushal, S., DasGupta, D., Prashar, B. & Bhardwaj, A. Electrocardiographic manifestations of healthy residents of a tribal Himalayan village. J. Assoc. Physicians India 43, 15-16 (1995).
67. Clinical Trials RegistryIndia. Panarrhythmia and Heart Failure Registry [online], http:// www.ctri.nic.in/Clinicaltrials/pmaindet2.php? trialid=203 (2012).
68. Zubaid, M. et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circ. Cardiovasc. Qual. Outcomes 4, 477-482 (2011).
69. Maru, M. Atrial fibrillation and embolic complications. East Afr. Med. J. 74, 3-5 (1997).
70. Sliwa, K. et al. Predisposing factors and incidence of newly diagnosed atrial fibrillation in an urban African community: insights from the Heart of Soweto Study. Heart 96, 1878-1882 (2010).
71. Oldgren, J. et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 129, 1568-1576 (2014).
72. Iung, B. & Vahanian, A. Epidemiology of valvular heart disease in the adult. Nat. Rev. Cardiol. 8, 162-172 (2011).
73. Salam, A. M., AlBinali, H. A., Al-Mulla, A. W., Singh, R. & Al Suwaidi, J. Secular trends, treatments, and outcomes of Middle Eastern Arab and South Asian patients hospitalized with atrial fibrillation: insights from a 20-year registry in Qatar (1991-2010). Angiology 64, 498-504 (2013).
74. Lee, K. S. et al. Prevalence of atrial fibrillation in middle-aged people in Korea: the Korean Genome and Epidemiology Study. Korean Circ. J. 38, 601-605 (2008).
75. Uyarel, H. et al. Incidence, prevalence, and mortality estimates for chronic atrial fibrillation in Turkish adults. Turk. Kardiyol. Dern. Ar. 36, 214-222 (2008).
76. Lloyd-Jones, D. M. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110, 1042-1046 (2004).
77. Heeringa, J. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 27, 949-953 (2006).
78. Lim, S. S. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224-2260 (2012).
79. Kelly, T., Yang, W., Chen, C. S., Reynolds, K. & He, J. Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. (Lond.) 32, 1431-1437 (2008).
80. Wang, T. J. et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292, 2471-2477 (2004).
81. Wanahita, N. et al. Atrial fibrillation and obesity results of a meta-analysis. Am. Heart J. 155, 310-315 (2008).
82. Frost, L., Hune, L. J. & Vestergaard, P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am. J. Med. 118, 489-495 (2005).
83. Guize, L., Thomas, F., Bean, K., Benetos, A. & Pannier, B. Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up [French]. Bull. Acad. Natl Med. 191, 791-803 (2007).
84. Tsang, T. S. et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur. Heart J. 29, 2227-2233 (2008).
85. Zhang, X. et al. Association of obesity and atrial fibrillation among middle-aged and elderly Chinese. Int. J. Obes. (Lond.) 33, 1318-1325 (2009).
86. Dublin, S. et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch. Intern. Med. 166, 2322-2328 (2006).
87. Watanabe, H. et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata Preventive Medicine Study. Circulation 117, 1255-1260 (2008).
88. Guijian, L. et al. Impact of body mass index on atrial fibrillation recurrence: a meta-analysis of observational studies. Pacing Clin. Electrophysiol. 36, 748-756 (2013).
89. Huxley, R. R. et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123, 1501-1508 (2011).
90. Thacker, E. L. et al. Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation. J. Gen. Intern. Med. 28, 247-253 (2013).
91. Kakkar, A. K. et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS ONE 8, e63479 (2013).
92. Liu, Y., Liu, H., Dong, L., Chen, J. & Guo, J. Prevalence of atrial fibrillation in hospitalized patients over 40 years old: ten-year data from the Peoples Hospital of Peking University. Acta Cardiol. 65, 221-224 (2010).
93. Conen, D. et al. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 119, 2146-2152 (2009).
94. Mitchell, G. F. et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA 297, 709-715 (2007).
95. Gamra, H. et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch. Cardiovasc. Dis. 107, 77-87 (2014).
96. Chiang, C.-E. et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ. Arrhythm. Electrophysiol. 5, 632-639 (2012).
97. Alonso, A. et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J. Am. Heart Assoc. 2, e000102 (2013).
98. Krahn, A. D., Manfreda, J., Tate, R. B., Mathewson, F. A. & Cuddy, T. E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am. J. Med. 98, 476-484 (1995).
99. Goto, S. et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am. Heart J. 156, 855-863 (2008).
100. Schnabel, R. B. et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373, 739-745 (2009).
101. Uchiyama, S. et al. Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: a Japanese Multicenter Cooperative Registry. J. Stroke Cerebrovasc. Dis. 19, 190-197 (2010).
102. Jabre, P. et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation 123, 2094-2100 (2011).
103. Jabre, P. et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation 123, 1587-1593 (2011).
104. Iguchi, Y. et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: analysis of 41,436 non-employee residents in Kurashiki-city. Circ. J. 72, 909-913 (2008).
105. Kannel, W. B., Abbott, R. D., Savage, D. D. & McNamara, P. M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N. Engl. J. Med. 306, 1018-1022 (1982).
106. Ntep-Gweth, M. et al. Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. Europace 12, 482-487 (2010).
107. Hersi, A. et al. Saudi Atrial Fibrillation Survey: national, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of patients with atrial fibrillation. Angiology http://dx.doi.org/10.1177/ 0003319714529180.
108. Bhardwaj, R. Atrial fibrillation in a tertiary care institute-a prospective study. Indian Heart J. 64, 476-478 (2012).
109. Cappola, A. R. et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295, 1033-1041 (2006).
110. Selmer, C. et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 345, e7895 (2012).
111. Kodama, S. et al. Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J. Am. Coll. Cardiol. 57, 427-436 (2011).
112. Aviles, R. J. et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108, 3006-3010 (2003).
113. Marott, S. C. et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J. Am. Coll. Cardiol. 56, 789-795 (2010).
114. Schnabel, R. B. et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 121, 200-207 (2010).
115. Ofman, P. et al. Regular physical activity and risk of atrial fibrillation: a systematic review and meta-analysis. Circ. Arrhythm. Electrophysiol. 6, 252-256 (2013).
116. Aizer, A. et al. Relation of vigorous exercise to risk of atrial fibrillation. Am. J. Cardiol. 103, 1572-1577 (2009).
117. Mozaffarian, D., Furberg, C. D., Psaty, B. M. & Siscovick, D. Physical activity and incidence of atrial fibrillation in older adults: the Cardiovascular Health Study. Circulation 118, 800-807 (2008).
118. Arnar, D. O. et al. Familial aggregation of atrial fibrillation in Iceland. Eur. Heart J. 27, 708-712 (2006).
119. Christophersen, I. E. et al. Familial aggregation of atrial fibrillation: a study in Danish twins. Circ. Arrhythm. Electrophysiol. 2, 378-383 (2009).
120. Fox, C. S. et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 291, 2851-2855 (2004).
121. Zoller, B., Ohlsson, H., Sundquist, J. & Sundquist, K. High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden. J. Am. Heart Assoc. 2, e003384 (2013).
122. Li, C. et al. Significant association of SNP rs2106261 in the ZFHX3 gene with atrial fibrillation in a Chinese Han GeneID population. Hum. Genet. 129, 239-246 (2011).
123. Shi, L. et al. Assessment of association of rs2200733 on chromosome 4q25 with atrial fibrillation and ischemic stroke in a Chinese Han population. Hum. Genet. 126, 843-849 (2009).
124. Ellinor, P. T. et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat. Genet. 44, 670-675 (2012).
125. Rienstra, M., McManus, D. D. & Benjamin, E. J. Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision making? Circulation 125, e941-e946 (2012)
126. Gage, B. F. et al. Validation of clinical classification schemes for predicting stroke. JAMA 285, 2864-2870 (2001).
127. Schnabel, R. B. et al. Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur. J. Heart Fail. 15, 843-849 (2013).
128. Suzuki, S. et al. A new scoring system for evaluating the risk of heart failure events in Japanese patients with atrial fibrillation. Am. J. Cardiol. 110, 678-682 (2012).
129. Wang, T. J. et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107, 2920-2925 (2003).
130. Kawabata-Yoshihara, L. A. et al. Atrial fibrillation and dementia: results from the Sao Paulo Ageing & Health Study. Arq. Bras. Cardiol. 99, 1108-1114 (2012).
131. Stefansdottir, H. et al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke 44, 1020-1025 (2013).
132. Thacker, E. L. et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology 81, 119-125 (2013).
133. Bjorck, S., Palaszewski, B., Friberg, L. & Bergfeldt, L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 44, 3103-3108 (2013).
134. Guo, Y. et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. Int. J. Cardiol. 168, 904-909 (2013).
135. Komatsu, T. et al. Relationship between CHA2DS2-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation without receiving anticoagulant therapy. J. Cardiol. 59, 321-328 (2012).
136. Chen, X., Wang, H., Zhang, H. & Xiao, C. The prevalence survey and influential factors of atrial fibrillation in Taiyuan. Heart 97, A91-A92 (2011).
137. Jorgensen, H. S., Nakayama, H., Reith, J., Raaschou, H. O. & Olsen, T. S. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 27, 1765-1769 (1996).
138. McGrath, E. R. et al. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology 81, 825-832 (2013).
139. Liao, J., Khalid, Z., Scallan, C., Morillo, C. & ODonnell, M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 38, 2935-2940 (2007).
140. Sen, S. et al. Racial-ethnic differences in stroke risk factors and subtypes: results of a prospective hospital-based registry. Int. J. Neurosci. 123, 568-574 (2013).
141. Hanchate, A. D., Schwamm, L. H., Huang, W. & Hylek, E. M. Comparison of ischemic stroke outcomes and patient and hospital characteristics by race/ethnicity and socioeconomic status. Stroke 44, 469-476 (2013).
142. Mahajan, S. et al. Stroke at moderate altitude. J. Assoc. Physicians India 52, 699-702 (2004).
143. Syed, N. et al. Ischemic stroke subtypes in Pakistan: the Aga Khan university stroke data bank. J. Pak. Med. Assoc. 53, 584-588 (2003).
144. Walker, R. W. et al. Electrocardiographic assessment of coronary artery disease and stroke risk factors in rural and urban Tanzania: a case-control study. J. Stroke Cerebrovasc. Dis. 23, 315-320 (2013).
145. Tagawa, M. et al. Evaluating patients with acute ischemic stroke with special reference to newly developed atrial fibrillation in cerebral embolism. Pacing Clin. Electrophysiol. 30, 1121-1128 (2007).
146. Kimura, K., Minematsu, K., Yamaguchi, T. & Japan Multicenter Stroke Investigators Collaboration (J-MUSIC). Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J. Neurol. Neurosurg. Psychiatry 76, 679-683 (2005).
147. Birman-Deych, E., Radford, M. J., Nilasena, D. S. & Gage, B. F. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 37, 1070-1074 (2006).
148. Brainin, M., Teuschl, Y. & Kalra, L. Acute treatment and long-term management of stroke in developing countries. Lancet Neurol. 6, 553-561 (2007).
149. Hori, M. et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44, 1891-1896 (2013).
150. Albertsen, I. E. et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke 44, 1329-1336 (2013).
151. Sanderson, S., Emery, J. & Higgins, J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7, 97-104 (2005).
152. Tham, L. S. et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80, 346-355 (2006).
153. Pathare, A. et al. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. J. Hum. Genet. 57, 665-669 (2012).
154. Soares, R. A. et al. CYP2C9 and VKORC1 polymorphisms are differently distributed in the Brazilian population according to self-declared ethnicity or genetic ancestry. Genet. Test. Mol. Biomarkers 16, 957-963 (2012).
155. Kimmel, S. E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369, 2283-2293 (2013).
156. Chan, S. L., Suo, C., Chia, K. S. & Teo, Y. Y. The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. Pharmacogenomics 13, 1247-1256 (2012).
157. Perera, M. A. et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382, 790-796 (2013).
158. Hartter, S., Yamamura, N., Stangier, J., Reilly, P. A. & Clemens, A. Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Thromb. Haemost. 107, 260-269 (2012).
159. Hori, M. et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillationsub-analysis in Japanese population in RE-LY trial. Circ. J. 75, 800-805 (2011).
160. Liesenfeld, K. H. et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J. Thromb. Haemost. 9, 2168-2175 (2011).
161. Reilly, P. A. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J. Am. Coll. Cardiol. 63, 321-328 (2014).
162. Lin, H. J. et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27, 1760-1764 (1996).
163. Marini, C. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36, 1115-1119 (2005).
164. Wong, K. S. Risk factors for early death in acute ischemic stroke and intracerebral hemorrhage: a prospective hospital-based study in Asia. Asian Acute Stroke Advisory Panel. Stroke 30, 2326-2330 (1999).
165. Huang, Y. C. et al. The impact factors on the cost and length of stay among acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 22, e152-158 (2013).
166. Gattellari, M., Goumas, C., Aitken, R. & Worthington, J. M. Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM study (a Program of Research Informing Stroke Management). Cerebrovasc. Dis. 32, 370-382 (2011).
167. Lamassa, M. et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 32, 392-398 (2001).
168. Lin, S. et al. Characteristics, treatment and outcome of ischemic stroke with atrial fibrillation in a Chinese hospital-based stroke study. Cerebrovasc. Dis. 31, 419-426 (2011).
169. Hannon, N. et al. Improved late survival and disability after stroke with therapeutic anticoagulation for atrial fibrillation: a population study. Stroke 42, 2503-2508 (2011).
170. Sussman, M. et al. Impact of atrial fibrillation on stroke-related healthcare costs. J. Am. Heart Assoc. 2, e000479 (2013).
171. Kalantarian, S., Stern, T. A., Mansour, M. & Ruskin, J. N. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 158, 338-346 (2013).
172. Marzona, I. et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ 184, E329-E336 (2012).
173. Miyasaka, Y. et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur. Heart J. 28, 1962-1967 (2007).
174. Damasceno, A. et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch. Intern. Med. 172, 1386-1394 (2012).
175. Karaye, K. M. & Sani, M. U. Electrocardiographic abnormalities in patients with heart failure. Cardiovasc. J. Afr. 19, 22-25 (2007).
176. Ahmed, A. & Perry, G. J. Incident atrial fibrillation and mortality in older adults with heart failure. Eur. J. Heart Fail. 7, 1118-1121 (2005).
177. McManus, D. D. et al. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J. Am. Heart Assoc. 2, e005694 (2013).
178. Chamberlain, A. M., Redfield, M. M., Alonso, A., Weston, S. A. & Roger, V. L. Atrial fibrillation and mortality in heart failure: a community study. Circ. Heart Fail. 4, 740-746 (2011).
179. Mamas, M. A. et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur. J. Heart Fail. 11, 676-683 (2009).
180. Wasywich, C. A. et al. Atrial fibrillation and the risk of death in patients with heart failure: a literature-based meta-analysis. Intern. Med. J. 40, 347-356 (2010).
181. Dzudie, A. et al. Prognostic significance of ECG abnormalities for mortality risk in acute heart failure: insight from the Sub-Saharan Africa Survey of Heart Failure (THESUS-HF). J. Card. Fail. 20, 45-52 (2014).
182. Ruff, C. T. et al. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int. J. Cardiol. 170, 413-418 (2014).
183. Lubitz, S. A. et al. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J. Am. Heart Assoc. 2, e000126 (2013).
184. Chen, L. Y. et al. Atrial fibrillation and the risk of sudden cardiac death: the Atherosclerosis Risk in Communities Study and Cardiovascular Health Study. JAMA Intern. Med. 173, 29-35 (2013).
185. Duncan, M. E., Pitcher, A. & Goldacre, M. J. Atrial fibrillation as a cause of death increased steeply in England between 1995 and 2010. Europace 16, 797-802 (2014).
186. Chien, K.-L. et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int. J. Cardiol. 139, 173-180 (2010).
187. Suzuki, S. et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ. J. 72, 914-920 (2008).
188. Fuster, V. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114, e257-e354 (2006).
189. European Heart Rhythm Association et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31, 2369-2429 (2010).
190. Wyse, D. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833 (2002).
191. Hagens, V. E. et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J. Am. Coll. Cardiol. 43, 241-247 (2004).
192. Nieuwlaat, R. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur. Heart. J. 26, 2422-2434 (2005).
193. Nabauer, M. et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 11, 423-434 (2009).
194. Wen-Hang, Q. I. Retrospective investigation of hospitalised patients with atrial fibrillation in mainland China. Int. J. Cardiol. 105, 283-287 (2005).
195. Zhang, S. Atrial fibrillation in mainland China: epidemiology and current management. Heart 95, 1052-1055 (2009).
196. Hu, D. & Sun, Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J. Am. Coll. Cardiol. 52, 865-868 (2008).
197. Chen, Y. H., Chen, H., Wu, Y. & Hu, D. Cardiac electrophysiology in China. Heart Rhythm 4, 862 (2007).
198. Ruigomez, A., Johansson, S., Wallander, M. A. & Rodriguez, L. A. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J. Clin. Epidemiol. 55, 358-363 (2002).
199. Fang, M. C., Stafford, R. S., Ruskin, J. N. & Singer, D. E. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch. Intern. Med. 164, 55-60 (2004).
200. Chang, S. S. et al. Digoxin use is associated with increased risk of stroke in patients with non-valvular atrial fibrillationa nationwide population-based cohort study. Int. J. Cardiol. 169, e26-e27 (2013).
201. Cappato, R. et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ. Arrhythm. Electrophysiol. 3, 32-38 (2010).
202. Gupta, A. et al. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ. Arrhythm. Electrophysiol. 6, 1082-1088 (2013).
203. Cappato, R. et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 111, 1100-1105 (2005).
204. Laguna, P., Martn, A., del Arco, C. & Gargantilla, P. Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study. Ann. Emerg. Med. 44, 3-11 (2004).
205. Scott, P. A. Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. Stroke 33, 2664-2669 (2002).
206. Andersen, K. K. & Olsen, T. S. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke. Stroke 38, 259-263 (2007).
207. Apostolakis, S. et al. Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: the Gulf SAFE registry. Int. J. Cardiol. 168, 1644-1646 (2013).
208. Fornari, L. S. et al. Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. J. Thromb. Thrombolysis 23, 65-71 (2007).
209. Lakshminarayan, K., Solid, C. A., Collins, A. J., Anderson, D. C. & Herzog, C. A. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke 37, 1969-1974 (2006).
210. Marshall, I. J., Wang, Y., McKevitt, C., Rudd, A. G. & Wolfe, C. D. Trends in risk factor prevalence and management before first stroke: data from the South London Stroke Register 1995-2011. Stroke 44, 1809-1816 (2013).
211. Mathur, R. et al. Ethnicity and stroke risk in patients with atrial fibrillation. Heart 99, 1087-1092 (2013).
212. Gadzhanova, S. V., Roughead, E. E. & Bartlett, M. J. Improving cardiovascular disease management in Australia: NPS MedicineWise. Med. J. Aust. 199, 192-195 (2013).
213. Jedsadayanmata, A. Patterns and adherence to guidelines of antithrombotic therapy in Thai patients with nonvalvular atrial fibrillation. J. Med. Assoc. Thai. 96, 91-98 (2013).
214. Tomita, F. et al. Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan. Jpn. Circ. J. 64, 653-658 (2000).
215. Atarashi, H. et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ. J. 75, 1328-1333 (2011).
216. Singer, D. E. et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J. Am. Heart Assoc. 2, e000067 (2013).
217. Ghaswalla, P. K., Harpe, S. E. & Slattum, P. W. Warfarin use in nursing home residents: results from the 2004 national nursing home survey. Am. J. Geriatr. Pharmacother. 10, 25-36.e2 (2012).
218. Gao, Q. et al. Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the ChinaQUEST (Quality Evaluation of Stroke Care and Treatment) registry study. Int. J. Stroke 8, 150-154 (2012).
219. Maurice, M. F., Di Tommaso, F., Zgaig, M., Stutzbach, P. & Iglesias, R. Thromboprophylaxis of atrial fibrillation. Analysis of the Argentinean National Register of Atrial Fibrillation and Atrial Flutter (RENAFA) [abstract]. J. Cardiovasc. Electrophysiol. 22 (Suppl. 1), S102 (2011).
220. Man-Son-Hing, M., Nichol, G., Lau, A. & Laupacis, A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch. Intern. Med. 159, 677-685 (1999).
221. Gattellari, M., Worthington, J., Zwar, N. & Middleton, S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke 39, 227-230 (2008).
222. Donz, J. et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am. J. Med. 125, 773-778 (2012).
223. Sellers, M. B. & Newby, L. K. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am. Heart J. 161, 241-246 (2011).
224. Fang, M. C. et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am. J. Med. 120, 700-705 (2007).
225. Suzuki, S. et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ. J. 71, 761-765 (2007).
226. Shen, A. Y., Yao, J. F., Brar, S. S., Jorgensen, M. B. & Chen, W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J. Am. Coll. Cardiol. 50, 309-315 (2007).
227. Ringborg, A. et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 10, 403-411 (2008).
228. Wattigney, W. A., Mensah, G. A. & Croft, J. B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108, 711-716 (2003).
229. Wong, C. X., Brooks, A. G., Leong, D. P., Roberts-Thomson, K. C. & Sanders, P. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch. Intern. Med. 172, 739-741 (2012).
230. Benjamin, E. J. et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation 119, 606-618 (2009).
231. Guthrie, B., Payne, K., Alderson, P., McMurdo, M. E. & Mercer, S. W. Adapting clinical guidelines to take account of multimorbidity. BMJ 345, e6341 (2012).
232. Piccini, J. P. et al. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. Eur. Heart J. 35, 250-256 (2014).
233. Hess, P. L. et al. Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am. J. Med. 126, 625-632.e1 (2013).
234. Hendriks, J. M. et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur. Heart J. 33, 2692-2699 (2012).
235. Abed, H. S. et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310, 2050-2060 (2013).
236. McManus, D. D. et al. A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation. Heart Rhythm 10, 315-319 (2013).
237. Gradl, S., Kugler, P., Lohmuller, C. & Eskofier, B. Real-time ECG monitoring and arrhythmia detection using Android-based mobile devices. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2012, 2452-2455 (2012).
238. Lau, J. K. et al. iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int. J. Cardiol. 165, 193-194 (2013).
239. Rosenberg, M. A., Samuel, M., Thosani, A. & Zimetbaum, P. J. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. Pacing Clin. Electrophysiol. 36, 328-333 (2013).
240. Hendrikx, T., Hornsten, R., Rosenqvist, M. & Sandstrom, H. Screening for atrial fibrillation with baseline and intermittent ECG recording in an out-of-hospital population. BMC Cardiovasc. Disord. 13, 41 (2013).
241. The World Bank. GDP per capita, PPP (current international $) [online], http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD?order=wbapi-data-value-2012+wbapi-data-value+wbapi-data-value-last&sort=desc (2013).
242. Kirley, K., Qato, D. M., Kornfield, R., Stafford, R. S. & Alexander, G. C. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ. Cardiovasc. Qual. Outcomes 5, 615-621 (2012).
243. Rasool, S. & Haq, Z. Anticoagulation therapy in high risk patients with atrial fibrillation: retrospective study in a regional hospital. JLUMHS 8, 136-138 (2009).
244. Arce, M. et al. Frecuencia de fibrilacin auricular y tratamiento con anticoagulantes orales en pacientes con marcapasos definitivo [Spanish]. Invest. Clin. 52, 58-68 (2011).
245. Habibzadeh, F., Yadollahie, M., Roshanipoor, M. & Haghighi, A. Prevalence of atrial fibrillation in a primary health care centre in Fars province, Islamic Republic of Iran. East Mediterr. Health J. 10, 147-151 (2004).
246. Inoue, H. et al. Sex-related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J-TRACE. Circ. J. 74, 650-654 (2010).
247. Lee, S. H. et al. Risk factors between patients with lone and non-lone atrial fibrillation. J. Korean Med. Sci. 28, 1174-1180 (2013).
248. Bennett, D., Abate, J. & Abrahamson, P. E. Characteristics of patients with venous thromboembolism and atrial fibrillation in Venezuela. BMC Public Health 11, 415 (2011).
249. Weir, N., Sandercock, P., Lewis, S., Signorini, D. & Warlow, C. Variations between countries in outcome after stroke in the International Stroke Trial (IST). Stroke 32, 1370-1377 (2001).
250. Gonzlez Toledo, M. E. et al. Atrial fibrillation detected after acute ischemic stroke: evidence supporting the neurogenic hypothesis. J. Stroke Cerebrovasc. Dis. 22, e486-e491 (2013).
251. Mallmann, A. B., Fuchs, S. C., Gus, M., Fuchs, F. D. & Moreira, L. B. Population-attributable risks for ischemic stroke in a community in South Brazil: a case-control study. PLoS ONE 7, e35680 (2012).
252. Ghandehari, K. & Mood, Z. I. Cardioembolic strokes in Eastern Iran and the importance of rheumatic valvular disease. Turk. J. Med. Sci. 36, 361-364 (2006).
253. Bahou, Y., Hamid, H. & Raqab, M. Z. Ischemic stroke in Jordan 2000 to 2002: a two-year, hospital-based study. J. Stroke Cerebrovasc. Dis. 13, 81-84 (2004).
254. Devkota, K. C., Thapamagar, S. B. & Malla, S. Retrospective analysis of stroke and its risk factors at Nepal Medical College Teaching Hospital. Nepal Med. Coll. J. 8, 269-275 (2006).
255. Alkali, N. et al. Stroke risk factors, subtypes, and 30-day case fatality in Abuja, Nigeria. Niger. Med. J. 54, 129-135 (2013).
256. Shafqat, S., Kelly, P. & Furie, K. Holter monitoring in the diagnosis of stroke mechanism. Intern. Med. J. 34, 305-309 (2004).
257. Deleu, D. et al. Ethnic variations in risk factor profile, pattern and recurrence of non-cardioembolic ischemic stroke. Arch. Med. Res. 37, 655-662 (2006).
258. Khan, F. Y. et al. Stroke in Qatar: a first prospective hospital-based study of acute stroke. J. Stroke Cerebrovasc. Dis. 17, 69-78 (2008).